Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. Clinics, [S. l.], v. 76, p. e3146, 2021. DOI: 10.6061/clinics/2021/e3146. Disponível em: https://revistas.usp.br/clinics/article/view/212977.. Acesso em: 20 may. 2024.